What is it about?
FcγR polymorphisms were implicated in pathogenesis of rheumatoid arthritis (RA) and treatment efficacy of TNF inhibitors (TNFi). We have shown in Chinese RA patients that FcγRIIa-131H allele may have a protective role in autoantibody production and might be a biomarker for predicting good response to TNFi.
Featured Image
Why is it important?
Two significant findings are: 1) FcγRIIa-131 may be involved in pathogenesis of RA. 2) FcγRIIa-131might be used to predicting treatment efficacy to TNFi in RA patients in Chinese population.
Perspectives
SNPs of FcγRs in pathogenesis of RA and in predicting therapeutic efficacy of TNFi treatment have been inadequately studied in Chinese RA patients. In our study we identified FcγRIIa-131H as a pharmacogenomics biomarker in predicting autoantibody production and good response to TNFi treatment. Further confirmation of the association and investigation of biological mechanisms may help to disclose the role of FcγR polymorphisms in RA.
Dr. Yining YS Sun
First Affiliated Hospital, Xian Jiaotong University
Read the Original
This page is a summary of: Association of Fcgamma receptor type 2A and 3A genotypes with rheumatoid arthritis in Chinese population, Pharmacogenomics, February 2017, Future Medicine,
DOI: 10.2217/pgs-2016-0159.
You can read the full text:
Contributors
The following have contributed to this page
